Dutch biotechnology company Crucell NV (CRXL) Tuesday posted a second-quarter net loss due to tax charges and currency effects, but reported 32% revenue growth and confirmed its outlook for 2009.

The Dutch company, which makes vaccines for influenza, children's diseases and hepatitis B, reported a second quarter net loss of EUR1.8 million, compared with a net loss of EUR7.4 million a year earlier. Revenue rose 32% to EUR78.7 million, mainly driven by strong sales of Crucell's children's vaccine Quinvaxem.

Three analysts polled by Dow Jones Newswires forecast a net profit of EUR4.6 million and revenue of EUR84.8 million.

Crucell reiterated its guidance for 2009, saying it expects combined full-year 2009 total revenue and other operating income to grow by 20% at constant currencies.

Crucell shares closed at EUR17.40 Monday and have gained nearly 60% year-to-date. In January, Crucell pulled out of friendly takeover talks with U.S.-based Wyeth (WYE), which is set to merge with Pfizer Inc. (PFE).

Company Web site: http://www.crucell.com

-By Maarten van Tartwijk; Dow Jones Newswires; +31 20 571 5201; maarten.vantartwijk@dowjones.com